Head-to-head evidence
Alectinib vs Brigatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Alectinib · Alecensa
Marketed by Roche
NCT02075840 · Phase 3 · completed
Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.
Next expected readout: November 2026 · NCT05987956 (registry estimate)
Brigatinib
Marketed by Takeda Pharmaceutical Company
NCT02737501 · Phase 3 · completed
This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT04223596 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Brigatinib's landscape